Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.
Friedman CF, Manning-Geist BL, Zhou Q, Soumerai T, Holland A, Da Cruz Paula A, Green H, Ozsoy MA, Iasonos A, Hollmann T, Leitao MM Jr, Mueller JJ, Makker V, Tew WP, O'Cearbhaill RE, Liu YL, Rubinstein MM, Troso-Sandoval T, Lichtman SM, Schram A, Kyi C, Grisham RN, Causa Andrieu P, Wherry EJ, Aghajanian C, Weigelt B, Hensley ML, Zamarin D. Friedman CF, et al. Among authors: zamarin d. Nat Med. 2024 May;30(5):1330-1338. doi: 10.1038/s41591-024-02942-7. Epub 2024 Apr 23. Nat Med. 2024. PMID: 38653864 Free PMC article. Clinical Trial.
Immunotherapy of Melanoma.
Snyder A, Zamarin D, Wolchok JD. Snyder A, et al. Among authors: zamarin d. Prog Tumor Res. 2015;42:22-9. doi: 10.1159/000436998. Epub 2015 Sep 4. Prog Tumor Res. 2015. PMID: 26376963 Review.
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
Zamarin D, Ricca JM, Sadekova S, Oseledchyk A, Yu Y, Blumenschein WM, Wong J, Gigoux M, Merghoub T, Wolchok JD. Zamarin D, et al. J Clin Invest. 2018 Nov 1;128(11):5184. doi: 10.1172/JCI125039. Epub 2018 Oct 2. J Clin Invest. 2018. PMID: 30277478 Free PMC article. No abstract available.
Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.
Jiménez-Sánchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, Gill MB, Park KJ, Zivanovic O, Konner J, Ricca J, Zamarin D, Walther T, Aghajanian C, Wolchok JD, Sala E, Merghoub T, Snyder A, Miller ML. Jiménez-Sánchez A, et al. Among authors: zamarin d. Cell. 2017 Aug 24;170(5):927-938.e20. doi: 10.1016/j.cell.2017.07.025. Cell. 2017. PMID: 28841418 Free PMC article.
Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer.
Soumerai TE, Donoghue MTA, Bandlamudi C, Srinivasan P, Chang MT, Zamarin D, Cadoo KA, Grisham RN, O'Cearbhaill RE, Tew WP, Konner JA, Hensley ML, Makker V, Sabbatini P, Spriggs DR, Troso-Sandoval TA, Charen AS, Friedman C, Gorsky M, Schweber SJ, Middha S, Murali R, Chiang S, Park KJ, Soslow RA, Ladanyi M, Li BT, Mueller J, Weigelt B, Zehir A, Berger MF, Abu-Rustum NR, Aghajanian C, DeLair DF, Solit DB, Taylor BS, Hyman DM. Soumerai TE, et al. Among authors: zamarin d. Clin Cancer Res. 2018 Dec 1;24(23):5939-5947. doi: 10.1158/1078-0432.CCR-18-0412. Epub 2018 Aug 1. Clin Cancer Res. 2018. PMID: 30068706 Free PMC article.
Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.
Boland JL, Zhou Q, Martin M, Callahan MK, Konner J, O'Cearbhaill RE, Friedman CF, Tew W, Makker V, Grisham RN, Hensley ML, Zecca N, Iasonos AE, Snyder A, Hyman DM, Sabbatini P, Aghajanian C, Cadoo KA, Zamarin D. Boland JL, et al. Among authors: zamarin d. Gynecol Oncol. 2019 Feb;152(2):251-258. doi: 10.1016/j.ygyno.2018.11.025. Epub 2018 Nov 22. Gynecol Oncol. 2019. PMID: 30470581 Free PMC article.
145 results